|
gptkbp:instanceOf
|
gptkb:drug
analgesic
antitussive
opioid
|
|
gptkbp:ATCCode
|
N02AA59
R05DA04
|
|
gptkbp:bioavailability
|
~50% (oral)
|
|
gptkbp:brand
|
gptkb:Co-codamol
gptkb:Co-codaprin
gptkb:Cocodamol
gptkb:Codral
gptkb:Nurofen_Plus
gptkb:Panadeine
gptkb:Tylenol_with_Codeine
|
|
gptkbp:CASNumber
|
76-57-3
|
|
gptkbp:chemicalFormula
|
C18H21NO3
|
|
gptkbp:contraindication
|
breastfeeding
children under 12
|
|
gptkbp:discoveredBy
|
gptkb:Pierre_Jean_Robiquet
|
|
gptkbp:discoveredIn
|
1832
|
|
gptkbp:eliminationHalfLife
|
2.5–3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:foundIn
|
gptkb:opium_poppy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Codeine
|
|
gptkbp:isomerOf
|
gptkb:morphine
|
|
gptkbp:IUPACName
|
(5α,6α)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
|
|
gptkbp:KEGGID
|
D00295
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_(US)
Prescription only (various countries)
Schedule III (US, in combination)
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
converted to morphine in the body
|
|
gptkbp:MeSH_ID
|
D003001
|
|
gptkbp:metabolism
|
gptkb:morphine
gptkb:codeine-6-glucuronide
gptkb:norcodeine
liver
|
|
gptkbp:molecularWeight
|
299.364 g/mol
|
|
gptkbp:overdoseSymptoms
|
death
coma
respiratory depression
|
|
gptkbp:pregnancyCategory
|
C (US)
ADEC C (Australia)
|
|
gptkbp:proteinBinding
|
7–25%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL267
gptkb:DB00318
5284360
|
|
gptkbp:riskOfAddiction
|
yes
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
rectal
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
itching
drowsiness
respiratory depression
|
|
gptkbp:UNII
|
U62E3ZL0JZ
|
|
gptkbp:usedFor
|
pain relief
cough suppression
|
|
gptkbp:bfsParent
|
gptkb:Poppy
gptkb:Opiate
|
|
gptkbp:bfsLayer
|
5
|